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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the benefits and harms associated with clinical interventions for improving outcomes in women with antenatally diagnosed
or suspected MAP. We will compare conventional caesarean hysterectomy with uterine conservation treatments (together with adjunct
measures) in women who have been diagnosed antenatally with, or suspected to have, MAP.
B A C K G R O U N D
Morbidly adherent placenta (MAP) is a serious disorder in preg-
nancy, causing maternal deaths rates as high as 7% (Wortman
2013). The incidence of this condition has increased in recent
years, possibly due to a global rise in caesarean section rates
(Al-Khan 2014; Comstock 2014; Vogel 2015). Caesarean delivery
rates of 50% and above are common in some areas of China and
Brazil (Cavallaro 2013; Vogel 2015).
Recently, the World Health Organization (WHO), conducted a
worldwide systematic review. They concluded that a rise in cae-
sarean section rates up to 10%to 15%,was associatedwith reduced
maternal and perinatal mortality. In their subsequent worldwide
ecological study, they suggested, this could be due to local factors.
As caesarean section rates increased above 10% and up to 30%,
they observed no adverse outcomes on mortality rates. They were
unable to comment on rates above 30%. Furthermore, in geo-
graphical areas where facilities for caesarean section were not so
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well-developed or safe, the risks were higher (WHO 2015).
Description of the condition
MAP is a condition where the placental villi (finger like projec-
tions from the afterbirth) perforate the inner lining of the uterus
(womb). There are three subsets (RCOG 2011):
1. accreta: (75%) the placental villi attach to the myometrium
(womb muscle);
2. increta: (18%) the placental villi invade into the
myometrium (womb muscle); and
3. percreta: (7%) the placental villi invade through the
myometrium (womb muscle) (Berkley 2013; Wortman 2013).
Placenta accreta is a term that covers all the above (Perez-Delboy
2014). Some authors have described this condition as ’placental
attachment disorders’ or PAD (Comstock 2014).
MAP is further subdivided according to the number of placental
lobules attached to the uterus:
1. total: all the lobules;
2. partial: two lobules; and
3. focal: one lobule (Wortman 2013).
The earliest description of MAP was in the 1500s by Plater (
Wortman 2013). This condition was not often seen before the
1970s, as caesarean sections were rare before that time (Berkley
2013; Wortman 2013).
Currently, the incidence is variable and difficult to estimate. It is
quoted as one in 90 in Israel (Upson 2014), one in 540 in Thai-
land (Herath 2012), one in 533 in the United States of America
(USA) (Eller 2011; Perez-Delboy 2014), and 1.7 in 10,000 in the
United Kingdom (UK) (Fitzpatrick 2014). Importantly, the inci-
dence worldwide has increased to almost 10 times over the last 30
years (Eller 2011; Perez-Delboy 2014).
Identifying women with risk factors is important for the early
diagnosis andmanagement of the condition (Bowman 2014). The
major risk factors for MAP are: low-lying placenta (praevia) and
a history of past womb surgery (e.g. caesarean sections, uterine
curettage and myomectomy) (Bowman 2014; Comstock 2014).
However, other risk factors, such as age 35 years or older, in-
vitro fertilisation (IVF) pregnancy, high parity, smoking, history of
fibroids and abnormalities in the shape of the uterus are important
(Berkley 2013; Bowman 2014; Hayes 2011; Perez-Delboy 2014).
Prenatal diagnosis of MAP is useful in preventing adverse out-
comes for the mother and her baby (Comstock 2014; Palacios-
Jaraquemada 2013; Weiniger 2013). Diagnosis is performed by
ultrasound, which is very sensitive, but not very accurate. Special
investigations such as Doppler and magnetic resonance imaging
(MRI) are helpful, especially when the placenta is attached to the
back wall of the uterus (Garmi 2012; Jauniaux 2012; Weiniger
2013). Nevertheless, there are many cases diagnosed after delivery
of the baby. These cases can have serious consequences due to a
delay in diagnosis andmanagement. Additionally, inaccurate diag-
nosismay cause iatrogenic (caused by therapy or intervention) pre-
mature births, unwanted extensive surgery and protracted hospital
stay (Weiniger 2013). Clinicians must have a high index of suspi-
cion when these cases present as otherwise errors in management,
can be fatal to the woman (Berkley 2013; Palacios-Jaraquemada
2013).
Consequences of MAP include: massive haemorrhage, damage to
internal body organs, including the bladder, bowel and ureter,
blood clotting disorders, blood transfusion-related complications,
postoperative blood clots, infections, poor functioning of sev-
eral body organ systems and death of the mother (Berkley 2013;
Palacios-Jaraquemada 2013).
Description of the interventions and how these
may work
There are several interventions for MAP. The main focus of this
review will be on caesarean hysterectomy versus uterine preserva-
tion. We have described below, each important intervention and
how each of these might work.
Description of interventions
1. Caesarean hysterectomy
Surgical management consists of performing a planned hysterec-
tomy after delivering the baby, without attempting removal of the
placenta. This is the standard treatment worldwide, including the
USA (ACOG 2012; Amsalem 2011; Bowman 2014; Eller 2011;
Tan 2013; Wortman 2013). Caesarean hysterectomy, is the pre-
ferred treatment for massive obstetric haemorrhage unresponsive
to conservative measures. It often involves difficult and prolonged
surgery, severe bleeding and complications (Eller 2011). There are
several techniques and steps involved in performing this surgery,
including the type and place of the uterine incision, leaving the
placenta in-situ, removing the placenta completely and other ad-
junct measures as below.
2. Caesarean delivery and leaving the placenta in-situ
This intervention involves caesarean section for delivery of the
baby, followed by conservativemanagement of the placenta, which
is left in place, without any attempt at removal. This intervention
can then be subdivided further into:
1. planned delayed surgical placental delivery; or
2. planned conservative management of the placenta, i.e.
leaving the placenta in-situ for resorption without surgical
placental delivery (Perez-Delboy 2014).
The placenta sloughs off slowly over time, thus avoiding hysterec-
tomy (ACOG 2012; Clausen 2013; Langhoff-Roos 2013; Merz
2009).Various case-reports and case-series have shown that conser-
vative treatment is associated with lower maternal morbidity rates,
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but requires very close follow-ups (Lo 2014;Meyer 2012; Ramoni
2013; Torrega 2013; Tourette 2013). This approach avoids re-
moval of the womb (hysterectomy), and could be useful in popu-
lations that are surgically conservative.
3. One-step conservative surgery
This method is described by Clausen et al. for focal accreta
(Clausen 2014). It consists of cutting and removing the affected
area in thewomb togetherwith the afterbirth and then reconstruct-
ing the womb muscles in a single ’one-step procedure’ (Clausen
2014).
4. The complete placental removal method
The placenta is completely removed during surgery. This method
can cause severe bleeding. It is not recommended at present (
Sentilhes 2013).
5. Methotrexate
Methotrexate is a drug that stops rapidly dividing cells from mul-
tiplying and growing (anti-folic acid properties). Evidence of the
usage of this drug for managing MAP is controversial. The drug
may decrease the amount of blood flow to the placenta. The pla-
centa is slowly necrosed and expelled in small pieces (Wortman
2013). It is still unclear if this drug is useful on placental cells after
delivery of the fetus, as these cells are not rapidly dividing.Women,
allocated to this treatment, are perhaps at a risk of serious side-
effects and need close monitoring (Wortman 2013). Wortman et
al. noted that, many women expelled or extruded their placenta,
even without the using this drug (Wortman 2013). However, it
may still be an option in a carefully selected group of women with
MAP (Lin 2015).
How these interventions might work
Caesarean hysterectomy may significantly limit blood loss with
controlled, planned delivery of the placenta. Leaving the placenta
in-situ after planned caesarean delivery, allows for the body’s nat-
ural resorption of the abnormal placental tissue, thus helping in
uterine preservation. Similarly, one-step conservative surgery re-
moves just the affected abnormal tissue. The complete placental
removal methodmay also work by removing the affected placental
tissue completely.
Methotrexate acts by stopping the abnormally invading placental
tissue from dividing. The placenta is then resorbed over time, thus
enabling uterine preservation.
Description of other interventions and how
these may work
Timing of delivery
The proper time for delivery of pregnant womenwithMAP is con-
troversial (Wright 2013). In a large American study of more than
500 practitioners, about 41% recommended delivery between 34
to 36 weeks (Wright 2013). The Royal College of Obstetricians
and Gynaecologists (RCOG), suggest that uncomplicated cases
can be delivered safely at around 36 to 37 weeks (RCOG 2011).
Robinson et al. suggest delivery between 34 to 37weeks (Robinson
2010).
Earlier delivery (e.g. 34 weeks) is perhaps safer for the mother and
her child, as it might avoid massive haemorrhage or spontaneous
labour, which is often seen withMAP (including placenta praevia)
in the later weeks of pregnancy.
Tertiary referral
Referral to a tertiary level hospital and a multidisciplinary team
involvement could help improve outcomes in women with MAP
(Perez-Delboy 2014; Wortman 2013). Care in a tertiary facil-
ity might allow for better support in terms of maternal intensive
care, blood transfusion, anaesthesia services and better care of the
preterm neonate.
Pre-operative planning protocol/checklist
Preoperative checklists have been known to decrease maternal
morbidity in these complicated surgeries (El-Messidi 2012; Table
1). Therefore, checklists and protocols may help organise the team
by systematic preparation.
Adjuvant measures
The American College of Obstetricians and Gynecologists
(ACOG) recommend that caesarean hysterectomy is safer when
accompanied by other measures to arrest bleeding during surgery
(ACOG 2012;Wortman 2013). Ureteral stents may help the clin-
ician in identifying the ureter, to avoid ureteral injury during
surgery.
Haemostatic brace suturing (as the B-lynch suture or modified
compression sutures) may help resolve atony and cut the need for
caesarean hysterectomy and blood transfusion by compressing the
uterus.
Cell salvage may help by recycling the woman’s blood and thereby
reducing the need for blood transfusion.
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Why it is important to do this review
MAP is a condition that has serious adverse outcomes for the
mum and her baby. There are a number of management options
and mixed views on the ideal treatment, place of delivery and
timing of delivery. Data from high-quality studies, need analysis
in a thorough and systematic way, to check the usefulness and
efficiency of different approaches for managing MAP.
O B J E C T I V E S
To assess the benefits and harms associated with clinical interven-
tions for improving outcomes in women with antenatally diag-
nosed or suspectedMAP.We will compare conventional caesarean
hysterectomy with uterine conservation treatments (together with
adjunct measures) in women who have been diagnosed antenatally
with, or suspected to have, MAP.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) including those using quasi-
randomised and cluster-randomised designs will be eligible for in-
clusion. If just the abstract is available, we will contact the relevant
author or authors for a copy of the paper and will include the
study provisionally, as ’awaiting assessment’. Abstracts that have
detailed statistics would be considered for inclusion. Cross-over
studies would be excluded.
We plan to exclude studies where a diagnosis of MAP was not
made or suspected in the antenatal period and all studies where
the delivery method was not pre-planned.
Types of participants
The participants will be women who have had a confirmed or
suspected diagnosis of MAP in the antenatal period (before 34
completed weeks of gestation). All definitions will be according
to those used by the trial authors. If a study includes women with
multiple pregnancies, their data would be included into the re-
view and analysed according to the established criteria for multiple
pregnancy.
Types of interventions
We plan to look into certain types of interventions and pair-wise
comparisons as below, in our review (Higgins 2011).
Interventions
1. Planned caesarean hysterectomy.
2. Timing of delivery (e.g. < 36 weeks versus >= 36 weeks).
3. Tertiary care centre for delivery.
4. Pre-operative planning protocol or checklist or both.
5. Prophylactic occlusion balloon catheter (POBC) or uterine
artery embolisation (UAE).
6. Ureteral stents.
7. Uterine compression sutures (B-Lynch, etc).
8. Cell salvage.
9. Conservative management; this includes leaving the
placenta in-situ, one-step conservative surgery, or methotrexate.
Comparisons
1. Planned caesarean hysterectomy with or without adjuvant
measures compared with conservative management (i.e.
delivering the baby and preserving the uterus) with or without
adjuvant measures.
2. Delivery before 36 weeks compared with delivery at or
more than 36 weeks.
3. Delivery at a tertiary care centre versus delivery elsewhere.
4. Pre-operative planning protocol or checklist, or both, versus
none.
5. Use of POBC or UAE versus none.
6. Use of ureteral stents versus none.
7. Use of the uterine compression sutures (B-Lynch, etc)
during caesarean section compared with none.
8. Using cell salvage therapy versus none.
We may however, have to change our comparisons or add new
ones in the light of the type of data we collect (Higgins 2011).
Types of outcome measures
Primary outcomes
1. Maternal mortality.
2. Severe postpartum haemorrhage (blood loss of 1000 mL or
more within 24 hours after birth).
3. Perinatal mortality (stillbirth and neonatal death).
Secondary outcomes
Mother
1. Caesarean hysterectomy rates.
2. Any other significant blood loss in pregnancy and the
postpartum period (not included as a primary outcome above
and according to trial authors definition/s).
3. Anaemia.
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4. The number of units of blood transfused (and any other
blood products).
5. Intensive care unit (ICU) admission or readmission.
6. Duration of hospitalisation.
7. Serious maternal morbidity (e.g. thromboembolism,
coagulopathy, paralytic ileus, organ, injury: bladder or ureter or
bowel or all, vesicovaginal fistula, sepsis, shock).
Newborn
1. Serious neonatal morbidity (e.g. respiratory distress
syndrome, intraventricular haemorrhage, low Apgar scores,
convulsions, neonatal anaemia, hypertonia, hypotonia; etc.).
2. Preterm birth (< 37 weeks’ gestation) rate.
3. Small-for-gestational age (SGA) (below 10th centile on
customised birthweight chart, or as defined by trial authors).
4. Assisted ventilation of the newborn.
5. Low umbilical arterial blood pH (defined as less than 7.2,
or as by the trial authors).
6. Neonatal intensive care unit (NICU) care.
Note: All definitions above will be according to those used by trial
authors.
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by the Cochrane Pregnancy and Childbirth
Group.
Electronic searches
We will search the Cochrane Pregnancy and Childbirth Group’s
Trials Register by contacting the Trials Search Co-ordinator.
The Register is a database containing over 20,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate the PCG Trials Register including the
detailed search strategies forCENTRAL,MEDLINE,Embase and
CINAHL; the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current awareness
service, please follow this link to the editorial information about
the Cochrane Pregnancy and Childbirth Group in The Cochrane
Library and select the ‘Specialized Register ’ section from the op-
tions on the left side of the screen.
Briefly, the Cochrane Pregnancy and Childbirth Group’s Trials
Register is maintained by the Trials Search Co-ordinator and con-
tains trials identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth Group review topic (or topics),
and is then added to the Register. The Trials Search Co-ordinator
searches the Register for each reviewusing this topic number rather
than keywords. This results in a more specific search set that will
be fully accounted for in the relevant review sections (Included,
Excluded, Awaiting Classification or Ongoing).
In addition, we will search Open Grey, LILACS, HISA (Public
Health); Popline, MedCarib (Caribbean Health Sciences litera-
ture), WPRIM (WHOWestern Pacific region), Trip database and
BASE.
We will also search ClinicalTrials.gov and the WHO Interna-
tional Clinical Trials Registry Platform (ICTRP) for unpublished,
planned and ongoing trial reports.
See: Appendix 1 for the search terms, we plan to use for all these
sources.
Searching other resources
We will search the reference lists of retrieved papers. We will con-
tact colleagues and trial authors for any incomplete or unpublished
data (if applicable).
We will not apply any language or date restrictions.
Data collection and analysis
We will use the methods as described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
Selection of studies
At least two review authors from (RSG/AG/SQ/AB)will indepen-
dently assess eligibility according to the inclusion criteria and eval-
uate the methodological quality of the potentially eligible studies
(Higgins 2011). Any disagreement/s will be resolved by discussion
between the review authors and where necessary, a third review
author from (WF/VB/AA). We will contact authors of primary
studies for clarification if necessary. If just the abstract is available,
we will contact the relevant author/s for a copy of the paper and
will include the study provisionally, as ’awaiting assessment’. Some
studies where the abstract has detailed statistics and the paper is
unobtainable may be included.
We will create a study flow diagram to map out the number of
records identified, included and excluded directly into the Review
Manager software (RevMan 2014).
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Data extraction and management
At least two review authors from (RSG/AG/SQ/AB) will extract
the data and enter this into ReviewManager 2014. We will resolve
discrepancies through discussion or if required, we will consult
(VB/WF/AA). We will enter data directly into the Review Man-
ager Software (RevMan 2014) and check data for accuracy. When
information regarding any of the above is unclear, we will attempt
to contact authors of the original reports to provide further details
(Higgins 2011).
Assessment of risk of bias in included studies
Review author pairs (from RSG/AG/SQ/AB) will independently
assess risk of bias for each study using the criteria outlined in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). We will resolve any disagreement by discussion or
by involving VB/WF/AA. Where necessary, study authors will be
contacted for clarification.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake (Higgins 2011).
We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
We would prefer to use a cut-off point of 20%, which is the most
commonly used value (Higgins 2011 See Handbook section 8.13).
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
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• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias. These will be:
• if a potential source of bias was related to the specific study
design?
• if there was extreme baseline imbalance?
• if the study has been claimed to be fraudulent?
• if the trial was stopped early due to some data-dependent
process?
(Higgins 2011 See Handbook section 8.15).
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Handbook
(Higgins 2011). With reference to (1) to (6) above, we will assess
the likely magnitude and direction of the bias and whether we
consider it is likely to impact on the findings.
(8) Cluster-randomised studies
We will follow the guidance in section 16.3.2 Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) to assess par-
ticular biases in relation to cluster-randomised trials.
Assessing the quality of the body of evidence using
the GRADE approach
We plan to include a ’Summary of findings’ table for the main
(primary) outcomes listed above. We shall use the GRADEpro
(GRADEproGDT) (GRADEpro 2014) to import data from Re-
view Manager 5.3 (RevMan 2014) in order to create a ’Summary
of findings’ table (Higgins 2011).
Assessing the quality of the evidence using the
GRADE approach
The quality of the evidence will be assessed using the GRADE ap-
proach as outlined in the GRADE handbook in order to assess the
quality of the body of evidence relating to the following outcomes
for the main comparisons.
1. Maternal mortality.
2. Severe postpartum haemorrhage (blood loss of 1000 mL or
more within 24 hours after birth).
3. Perinatal mortality (stillbirth and neonatal death).
4. Caesarean hysterectomy rates
5. Intensive care unit (ICU) admission or readmission (for the
mother)
6. Duration of hospitalisation (for the mother)
The main comparisons for use in GRADE are listed below.
1. Planned caesarean hysterectomy with or without adjuvant
measures compared with conservative management (i.e.
delivering the baby and preserving the uterus) with or without
adjuvant measures.
2. Delivery before 36 weeks compared with delivery at or
more than 36 weeks.
3. Delivery at a tertiary care centre versus delivery elsewhere.
4. Pre-operative planning protocol or checklist, or both, versus
none.
5. Use of POBC or UAE versus none.
6. Use of ureteral stents versus none.
7. Use of the uterine compression sutures (B-Lynch, etc)
during caesarean section compared with none.
8. Using cell salvage therapy versus none.
GRADEpro Guideline Development Tool will be used to import
data from Review Manager 5.3 (RevMan 2014) in order to create
’Summary of findings’ tables. A summary of the intervention effect
and a measure of quality for each of the above outcomes will be
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as a summary risk
ratio (RR) with 95% confidence intervals (Higgins 2011).
7Interventions for improving pregnancy outcomes in antenatally diagnosed or suspected morbidly adherent placenta (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Continuous data
For continuous data, we will use the mean difference (MD) if
outcomes are measured in the same way between trials.We will use
the standardised mean difference (SMD) to combine trials that
measure the same outcome, but use different methods (Higgins
2011).
Unit of analysis issues
Cluster-randomised trials
We will include cluster-randomised trials in the analyses along
with individually-randomised trials. We will adjust the sample
sizes using themethods described in theHandbook (Higgins 2011)
using an estimate of the intra cluster correlation co-efficient (ICC)
derived from the trial, or from a similar trial or from a study of a
similar population.
If we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely (Higgins 2011).
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit (Higgins 2011).
Cross-over trials
Cross-over trials will not be included in this review.
Other unit of analysis issues
For studies that included multiple arms, three arms for example,
we will include these if any pair-wise comparisons if the interven-
tion groups are relevant to the review. However, where one arm
appears more than once on the same meta-analysis, the outcome
and denominator will be divided by the number of times it ap-
pears, to avoid multiple counting. For example, if the number of
events in the control group is an odd number, to reduce the risk
of overestimating effects in favour of the intervention group, we
will then halve it and round it down. For odd denominators (total
number of participants in the control group), we will round these
numbers upwards for the same reason (Higgins 2011).
Dealing with missing data
For included studies, we will note levels of attrition. Whenever
possible, the lead review author will contact the trial authors to
request missing data. Potential impact of missing data (known
or suspected) on findings of the review will be addressed in the
’Discussion’ section.
For all outcomes, we will carry out analyses, as far as possible, on
an intention-to-treat basis, i.e. we will attempt to include all par-
ticipants randomised to each group in the analyses and all partic-
ipants will be analysed in the group to which they were allocated,
regardless of whether or not they received the allocated interven-
tion. The denominator for each outcome in each trial will be the
number randomised minus any participants whose outcomes are
known to be missing.
We will carry out a sensitivity analysis (see below) instead of com-
pletely excluding trials with missing data.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We will regard heterogeneity as
substantial if an I² is greater than 30%and either the Tau² is greater
than zero, or there is a low P value (less than 0.10) in the Chi² test
for heterogeneity (Higgins 2011).
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis, we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it and to investigate whether asymmetry is
the result of small-study effects, publication bias, or other factors.
If it is likely that asymmetry is caused by small-study effects, we
will conduct sensitivity analysis to explore how this affects the re-
sults and conclusions of the meta-analysis.
Data synthesis
We will carry out statistical analysis using the Review Manager
software (RevMan 2014). We will use fixed-effect model for com-
bining data where it is reasonable to assume that studies are esti-
mating the same underlying treatment effect; i.e. where trials are
examining the same intervention, and the trials’ populations and
methods are judged sufficiently similar. If clinical heterogeneity
is sufficient to expect that the underlying treatment effects differ
between trials, or if substantial statistical heterogeneity is detected,
we will use the random-effects model to produce an overall sum-
mary (RevMan 2014).
The random-effects summary will be treated as the average of the
range of possible treatment effects and we will discuss the clinical
implications of treatment effects differing between trials. If the
average treatment effect is not clinically meaningful, we will not
combine trials.
If we use the random-effects analyses, the results will be presented
as the average treatment effect with 95% confidence intervals and
the estimates of Tau² and I².
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Subgroup analysis and investigation of heterogeneity
If we find significant heterogeneity, we will conduct a subgroup
analyses. We will consider whether an overall summary is useful,
and if it is, use random-effects analysis to produce it.
We plan to carry out the following subgroup analyses.
1. Previous caesarean births (none versus one or more).
2. Multiple pregnancy versus singleton pregnancy.
3. Total versus subtotal hysterectomy.
4. Elective versus emergency caesarean.
We will plan a subgroup analysis for all outcomes within the main
analysis.
We will assess subgroup differences by interaction tests available
within RevMan (RevMan 2014).We will report the results of sub-
group analyses quoting the Chi² statistic and P value, and the in-
teraction test I² value (Higgins 2011).We will contact trial authors
directly if we have any questions regarding their data (Higgins
2011).
Sensitivity analysis
We plan to carry out sensitivity analyses to explore the effect of
trial quality and small-study effects by excluding studies with risk
of bias and small sample size concerns from the analyses. This is to
decide, whether this will make any difference, to the overall result.
’High quality’ trials chosenwill be thosewith an adequate sequence
generation, where the allocation was adequately concealed and
those with an attrition rate (drop out) of less than of 20% (low
risk bias trials) (Higgins 2011).
In summary, we plan to carry out a sensitivity analysis by examin-
ing the effect on the findings, by excluding the following.
1. Trials at high risk of bias based on allocation concealment
or quasi-randomised trials.
2. Trials with small sample sizes.
3. Trials with a high attrition rate (> 20%).
The high risk domains that we plan to look into will include
(Higgins 2011) the following:
1. age range of the participants;
2. dosage of drugs used as methotrexate;
3. criteria used to define the comparator group;
4. time lines for the outcomes.
We will not exclude any missing data, but consider a sensitivity
analysis instead. We will contact trial authors directly if we have
any questions regarding their data (Higgins 2011).
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A D D I T I O N A L T A B L E S
Table 1. A multidisciplinary checklist for management of suspected placenta accreta (from Checklist from El-Messidi 2010)
Not applicable To do Pending Complete
Present/Absent
ULTRASOUND
Details of placentation:
Anterior
Posterior
LLP or previa
Loss of echo lucency be-
tween uterus and pla-
centa
Lacunae
Interruption of bladder-
uterine interface
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Table 1. A multidisciplinary checklist for management of suspected placenta accreta (from Checklist from El-Messidi 2010)
(Continued)
Suspected accreta by
colour Doppler
DESIGNATED
DELIVERY CENTRE
MRI Consultations.
MFM team
Anaesthesia
Interventional radiology
Most experienced sur-
geons (e.g., gyn-oncol-
ogy)
Urology
Neonatal ICU
LABORATORY Most
recent date:
2 to 4 units PRBCs cur-
rently on hold
CBC
Coagulation profile
INTRAOPERATIVE
PLANS
Notification of the main
OR (operating theatre)
Consent form
Preoperative internal il-
iac stents
4 units PRBC(packed
cells) on hold (or as re-
quested)
Hysterectomy tray avail-
able
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Table 1. A multidisciplinary checklist for management of suspected placenta accreta (from Checklist from El-Messidi 2010)
(Continued)
Cystoscopy set available/
urology team
Cell Saver
Neonatal team present
Experienced surgeons on
site
A P P E N D I C E S
Appendix 1. Search terms
Open Grey, LILACS, HISA (Public Health); Popline, MedCarib (Caribbean Health Sciences literature), WPRIM (WHO Western
Pacific region), Trip database and BASE.
(“adherent placenta” OR accreta OR increta OR percreta OR “placental attachment disorder”).
ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP):
We plan to search using simple terms for these databases. Each term will be searched separately and manually deduplicated:
adherent placenta
accreta
increta
percreta
placental attachment disorder
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